Wednesday, December 8, 2021 – Arlington, VA – Today, the Digital Therapeutics Alliance (DTA) is pleased to announce the results of their election to select the 2022 DTA Board of Directors. Two new members, Everett Crosland and Julia Strandberg, were elected by DTA members to serve on the Board along with current and re-elected Board members.
The 2022 DTA Board of Directors:
The Board of Directors supports DTA’s work to transform global healthcare by advancing digital therapeutics (DTx) and provides critical guidance related to the strategy and direction of the organization.
“Throughout DTA’s history, we have been fortunate to be represented by some of the most exceptional and pioneering leaders in the industry,” said Andy Molnar, DTA’s Chief Executive Officer. “Their efforts established a strong foundation and tremendous momentum. We are excited to work with this Board to continue that growth and provide patients and caregivers, clinicians, policymakers, and healthcare decision makers with reliable resources to meaningfully integrate DTx products into practice.”
DTA’s Board has set the strategic vision for the following global initiatives and will be instrumental in ensuring their successful execution:
Debra Reisenthel, Chair of the DTA Board of Directors, shares, “DTA membership has grown more than 75% since the beginning of this year. The increasingly diverse Alliance includes representatives from 17 countries and 5 continents, thus making the Board’s role that much more critical in providing strong leadership. We have accomplished a lot on behalf of our members to date and I am excited to work with this Board to accomplish our 2022 strategic priorities.”
###
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter.
Media Contact
Hannah Fairman
hfairman@dtxalliance.org
Arlington, VA — November 4, 2021 – As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance (DTA) welcomes the American Medical Association’s (AMA) Current Procedural Terminology (CPT®) Editorial Panel’s recent decision to clarify reporting of remote cognitive behavioral therapy (CBT) monitoring services. The changes to the CPT code set reflect the growing recognition that digital therapeutics (DTx) are an effective treatment for patients with mental health conditions and physicians should ultimately be reimbursed for their time spent prescribing, monitoring, and supplying online CBT technologies.
Access and affordability are two primary obstacles for many seeking mental healthcare, particularly in the most vulnerable populations. To address these challenges, a number of DTA’s members are delivering online CBT through their innovative products, making evidence-based treatments more accessible and improving patient outcomes. Thus, we are particularly excited to see the following updates from the Panel that will ensure physicians are able to deliver these interventions:
Tab # 43: Cognitive Behavioral Therapy Monitoring – Effective Date January 2023
These changes will allow providers to adequately describe time spent delivering these types of interventions, as Dr. Tom Megerian, MD, the Chief Medical Officer of one of DTA’s member companies, Cognito Therapeutics, recently stated, “As a prescriber, I have seen the value digital therapeutics provide to patients firsthand, but integrating them into patient care was challenging without a mechanism to report delivering these treatments. This update to the code set will help to ensure physicians are able to provide the therapies that work best for their patients.”
While these changes are an important step towards ensuring physicians are eventually compensated for the care they provide, obstacles remain for DTx products to have the reach and impact they could have on patient lives. Therefore, DTA is leading efforts to establish clear and scalable pathways for reimbursement to support the wider integration of these products into the larger healthcare ecosystem. To build on the positive changes of this code set update, further code changes should be considered as this emerging market takes shape and additional therapies become available. As a part of our broader efforts to ensure appropriate reimbursement for this category of medicine, DTA is also pursuing policy and legislative changes to establish a Medicare benefit category for digital therapeutics in addition to more clarity on coverage under state Medicaid programs.
###
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter.
CPT® is a registered trademark of the American Medical Association.
Media Contact:
Hannah Fairman
Digital Therapeutics Alliance
hfairman@dtxalliance.org
ARLINGTON, VA — September 23, 2021 – Today, the Digital Therapeutics Alliance (DTA), a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare, announced the launch of the DTA Resource Partner Program. The new initiative will accelerate the development and post-launch success of clinically evaluated digital therapeutics by building a best-in-class network of commercialization and product development service providers, each skilled in this rapidly advancing market.
For DTx products to have the reach and impact they could have on patient lives, DTA is leading efforts to support the wider integration of DTx products into the larger healthcare marketplace. DTA has seen membership grow by over 50% since the beginning of the year and represents an increasingly diverse coalition of digital therapeutics companies, medical device companies, non-profits, research organizations and pharmaceutical manufacturers invested in advancing the adoption of digital therapeutic products into mainstream healthcare. As member organizations complete clinical trials, receive regulatory clearance, and enter new markets, DTA’s Resource Partner Program will support the burgeoning industry during a critical stage. DTA Resource Partners are rigorously screened and vetted in order to collaborate with members of the Alliance.
“We are excited to be able to offer this new initiative, bringing together expertise and resources from across the industry to support our members,” said Andy Molnar, Chief Executive Officer of the Digital Therapeutics Alliance. “The Resource Partner Program will facilitate the development and commercialization of the next generation of innovative products, contributing to the transformation of global healthcare through expanded patient access, and improved clinical and economic outcomes.”
Today’s announcement named EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, as one of the first partners in the program. As a Resource Partner, EVERSANA, will begin by supporting DTA’s work to map global regulatory and reimbursement pathways for DTx products, to help members inform their strategic approach to achieve regulatory milestones that best fit their products. EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics. Among its many digital therapeutic engagements, EVERSANA was selected by MedRhythms to launch and commercialize MR-001, its patented software-based medical device designed to treat chronic stroke walking deficits.
“Digital therapeutics are transforming the concept of healthcare, yet few understand or appreciate the evolution underway. We have committed ourselves to a breakthrough, transformative approach to launch and commercialization of these innovations. It’s what this industry needs, and more importantly, what our patients deserve,” said Jim Lang, Chief Executive Officer of EVERSANA.
For more information on the DTA or details regarding the Resource Partners Program please visit dtxalliance.org.
###
Media Contacts:
DTA
Hannah Fairman
hfairman@dtxalliance.org
EVERSANA
Sarah Zwicky
Tel +1 (414) 434-4691
About DTA:
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding, adoption, and integration of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org or follow us on LinkedIn and Twitter.
About EVERSANA:
EVERSANA™ is the leading provider of global services to the life sciences industry. The company’s integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.
Thursday, June 24 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to announce the selection of Andy Molnar as the organization’s incoming Chief Executive Officer to lead the Alliance into its next phase of growth.
“Andy’s deep knowledge of the digital therapeutics industry, his expertise in market access for DTx products and his vision for DTA makes him the ideal CEO to lead us into the future. The Board is excited to partner with Andy as he executes on DTA’s important strategic priorities,” said Debra Reisenthel, Chair of the DTA Board of Directors and Founding CEO of Freespira.
As the leading international organization advancing evidence-based digital therapeutics, DTA is committed to broadening the understanding, adoption, and integration of clinically evaluated digital therapeutics with patients, clinicians, payors, and policymakers through education, advocacy, and cross-industry collaboration. With the DTx industry experiencing global growth, DTA has seen membership grow by 30% in the last six months. During this critical stage for the industry, DTA is expanding its capacity to lead international initiatives that will enable the clinical, organizational, and financial integration of DTx products into mainstream healthcare.
“This is an exceptionally exciting time for the digital therapeutics industry,” said Andy Molnar. “Alongside the members we serve, I look forward to driving the industry forward to help realize the massive opportunity digital therapeutics will bring to improve lives and health outcomes and streamline care.”
Andy has extensive experience in market access and has maintained a particular focus on making accessible and affordable solutions to resolve major gaps in healthcare. He most recently served as the Vice President of Market Access & Government Affairs for Cognoa, a DTA member company developing digital diagnostics and therapeutics for behavioral health conditions.
DTA’s Executive Director, Megan Coder, is transitioning to a new global leadership role within the organization, based in Europe, where she will expand DTA’s efforts related to international policy, lead the development of new content and resources, and grow cross-industry collaborative partnerships in support of DTA member goals.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
Tuesday, June 15 – Arlington, VA – To meet healthcare decision makers’ growing need for more consistency and clarity on how to evaluate, use, and benefit from digital therapeutics (DTx), the Digital Therapeutics Alliance (DTA) is leading the development of the DTx Value Assessment & Integration Guide.
This resource will provide a foundational template for entities undertaking the development of pathways to assess and integrate DTx products into clinical practice.
Over the last year, DTA has worked with members, our Payor Advisory Board, and Clinician Advisory Group to inform the development of this resource, which will provide a framework to help healthcare decision makers (HCDMs):
This summer, DTA is soliciting feedback from a targeted group of HCDMs, including payors, employers, governments, evaluators, health system administrators, and clinical leaders to review key aspects of this Guide and ensures it meets HCDM needs.
If you are a healthcare decision maker and would like to participate in this targeted feedback period, please send a message including your name, organization, position, and country to valueframework@dtxalliance.org.
Following this comment period, the DTx Value Assessment & Integration Guide will undergo final revisions and is expected to be available to the public later this year.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
Thursday, June 3 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to welcome Owen McCarthy, President and Co-Founder of MedRhythms, to the DTA Board of Directors. In support of DTA’s work to transform global healthcare by advancing digital therapeutics (DTx), the Board provides critical guidance related to the strategy and direction of the organization.
The DTA Board of Directors includes:
“It is a great honor to serve on the DTA Board of Directors,” shares Owen McCarthy. “I look forward to building on my perspective as a DTx manufacturer to help us continue elevating the industry to reach the many patients that need us.”
As DTx industry leaders, DTA member efforts are instrumental in providing patients and caregivers, clinicians, policy and healthcare decision makers with reliable resources to meaningfully integrate digital therapeutics into practice and transform global healthcare.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more, please visit: www.dtxalliance.org.
The Digital Therapeutics Alliance (DTA) is pleased to announce the search for a Chief Executive Officer (CEO) to lead the Alliance into its next phase of growth. Ideal candidates will have demonstrated the ability to lead an organization, devise industry-level strategy, execute initiatives that align with the Alliance’s mission and vision, and build impactful stakeholder and industry relationships. The CEO will be responsible for the Alliance’s ongoing strategy development, industry engagement, communications, policy and partnerships, and ongoing organization oversight.
Read more: CEO position description
Founded in 2017, DTA is a non-profit trade association of industry leaders and stakeholders engaged in the evidence-driven advancement of digital therapeutics. As the leading international organization on digital therapeutic thought leadership and education, the Digital Therapeutics Alliance provides patients, clinicians, payors, and policymakers with the necessary tools to evaluate and utilize DTx products.
DTA’s members – including organizations dedicated to manufacturing, evaluating, supporting, and utilizing DTx products – work to transform global healthcare by advancing high quality, clinically-validated digital therapeutics to improve clinical and health economic outcomes. Alliance members include 45+ companies from 15 countries across Asia Pacific, Europe, and North America.
The DTA team has grown over the past year to include a Director of Operations, Engagement Manager, and Administrative and Operations Coordinator. DTA’s current Executive Director is transitioning into a full-time role to support the CEO and organization through leadership of key organization initiatives, ongoing development of content, APAC & European partnerships and policy efforts, and external affairs.
Candidates for this role must be eligible to work in the United States, with a preference for the individual being based in the Washington, DC region. Applicants are encouraged to submit a resume and cover letter to apply@dtxalliance.org.
March 13, 2021 – The Digital Therapeutics Alliance (DTA) submitted comments related to Health and Human Services’ ‘Making Permanent Regulatory Flexibilities Provided During the COVID-19 Public Health Emergency by Exempting Certain Medical Devices From Premarket Notification Requirements’ (86 FR 4088), published on January 15, 2021.
Although DTA does not support HHS 86 FR 4088 as currently written, we propose the following steps for HHS and FDA:
DTA’s full comments are provided here.
Thursday, January 28 – Arlington, VA – The Digital Therapeutics Alliance (DTA) is pleased to welcome member company leaders to the DTA Board of Directors and Work Group leadership. In our effort to transform global healthcare by advancing digital therapeutics, we are grateful to work with each of the following individuals.
Board of Directors
The DTA Board of Directors provides critical guidance related to the strategy and direction of the organization. The newest member of DTA’s Board is Scott Kollins, Ph.D, Professor within the Department of Psychiatry and Behavioral Science at the Duke University School of Medicine, and Co-Lead Digital Health Solutions with Duke Clinical Research Institute.
DTA’s 2021 Executive Committee includes: Debra Reisenthel (Chair), Eddie Martucci (Vice-Chair), Pierre Leurent (Secretary), and Scott Kollins (Treasurer).
Board Chair, Debra Reisenthel shares: “I am honored to assume the role of Board Chair of DTA during this exciting time for the Alliance. We accomplished much on behalf of our members in 2020 and we look forward to continuing this momentum in 2021. Our focus this year will be on the following global initiatives: expanding payor reimbursement opportunities, educating healthcare providers on the efficacy and value of digital therapeutics, and building confidence in the application of digital therapeutics within the healthcare ecosystem.”
DTA Member Work Groups
In line with DTA’s growing global work, this year we are proud to launch three regionally-based work groups led by industry experts:
As DTA leads the digital therapeutic industry in 2021, our collective efforts will be instrumental in providing patients and caregivers, clinicians, policy and healthcare decision makers with reliable resources to meaningfully integrate DTx products into practice and transform global healthcare.
About DTA
The Digital Therapeutics Alliance (DTA) is a global non-profit trade association of industry leaders and stakeholders with the mission of broadening the understanding and adoption of digital therapeutics into healthcare. DTA works to enable expanded access to high quality, evidence-based digital therapeutics for patients, clinicians, and payors in order to improve clinical and health economic outcomes. To learn more please visit: www.dtxalliance.org.